当前位置: 首页 >> 检索结果
862. Manufactured Chemicals and Children's Health - The Need for New Law.
作者: The Consortium For Children's Environmental Health.;David A Wirth.;Maureen Cropper.;Daniel A Axelrad.;Caroline Bald.;Aruni Bhatnagar.;Linda S Birnbaum.;Thomas A Burke.;Thomas C Chiles.;Ken Geiser.;Carly Griffin.;Pushpam Kumar.;Daniele Mandrioli.;Yongjoon Park.;Hervé Raps.;Apolline Roger.;Ted R Smith.;J Christopher States.;Kurt Straif.;Joel A Tickner.;Wendy Wagner.;Zhanyun Wang.;Ella M Whitman.;Tracey J Woodruff.;Aroub Yousuf.;Philip J Landrigan.
来源: N Engl J Med. 2025年392卷3期299-305页 872. Human Infection with a Novel Tickborne Orthonairovirus Species in China.
作者: Ming-Zhu Zhang.;Cai Bian.;Run-Ze Ye.;Xiao-Ming Cui.;Yan-Li Chu.;Nan-Nan Yao.;Xiao-Wei Xu.;Jin-Ling Ye.;Lin Chen.;Ji-Hu Yang.;Xiao-Ling Su.;Lin Huang.;Xiao-Yu Shi.;Lin Zhao.;Yu-Guo Chen.;Yuan-Chun Zheng.;Xiao-Min Zheng.;Jia-Fu Jiang.;Wu-Chun Cao.
来源: N Engl J Med. 2025年392卷2期200-202页 877. A Comparison of Peripherally Inserted Central Catheter Materials.
作者: Amanda J Ullman.;Deanne August.;Tricia M Kleidon.;Rachel M Walker.;Nicole Marsh.;Andrew C Bulmer.;Ben Pearch.;Naomi Runnegar.;Joanne Leema.;Paul Lee-Archer.;Cathy Biles.;Victoria Gibson.;Ruth Royle.;Katrina Southam.;Joshua Byrnes.;Vineet Chopra.;Alan Coulthard.;Peter Mollee.;Claire M Rickard.;Patrick N A Harris.;Robert S Ware.
来源: N Engl J Med. 2025年392卷2期161-172页
New catheter materials for peripherally inserted central catheters (PICCs) may reduce the risk of device failure due to infectious, thrombotic, and catheter occlusion events. However, data from randomized trials comparing these catheters are lacking.
878. Clearance of Driver Mutations after Transplantation for Myelofibrosis.
作者: Nico Gagelmann.;Marie Quarder.;Anita Badbaran.;Kristin Rathje.;Dietlinde Janson.;Catherina Lück.;Johanna Richter.;Franziska Marquard.;Sofia Oechsler.;Radwan Massoud.;Evgeny Klyuchnikov.;Ina Rudolph.;Mathias Schäfersküpper.;Christian Niederwieser.;Silke Heidenreich.;Carolina Berger.;Boris Fehse.;Christine Wolschke.;Francis Ayuk.;Nicolaus Kröger.
来源: N Engl J Med. 2025年392卷2期150-160页
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation clearance after transplantation is unclear.
879. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.
作者: Yael C Cohen.;Hila Magen.;Moshe Gatt.;Michael Sebag.;Kihyun Kim.;Chang-Ki Min.;Enrique M Ocio.;Sung-Soo Yoon.;Michael P Chu.;Paula Rodríguez-Otero.;Irit Avivi.;Natalia A Quijano Cardé.;Ashwini Kumar.;Maria Krevvata.;Michelle R Peterson.;Lilla Di Scala.;Emma Scott.;Brandi Hilder.;Jill Vanak.;Arnob Banerjee.;Albert Oriol.;Daniel Morillo.;María-Victoria Mateos.; .
来源: N Engl J Med. 2025年392卷2期138-149页
Talquetamab (anti-G protein-coupled receptor family C group 5 member D) and teclistamab (anti-B-cell maturation antigen) are bispecific antibodies that activate T cells by targeting CD3 and that have been approved for the treatment of triple-class-exposed relapsed or refractory multiple myeloma.
|